SLNO
Income statement / Annual
Last year (2024), Soleno Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Soleno Therapeutics, Inc.'s net income was -$175.85 M.
See Soleno Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$1.55 B |
$1.45 M |
$387.56 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.19 M
|
$2.30 M
|
$1.92 M
|
$1.61 M
|
$1.51 M
|
$352.68 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.19 M
|
-$2.30 M
|
-$1.92 M
|
-$1.55 B
|
-$58.52 K
|
$34.87 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
-0.04
|
0.09
|
| Research and Development Expenses |
$78.57 M
|
$25.19 M
|
$15.27 M
|
$21.45 M
|
$23.19 M
|
$16.27 M
|
$7.18 M
|
$3.07 M
|
$5.18 M
|
$4.54 M
|
| General & Administrative Expenses |
$105.86 M
|
$13.48 M
|
$9.84 M
|
$10.81 M
|
$0.00
|
$0.00
|
$6.56 M
|
$6.58 M
|
$6.74 M
|
$6.14 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$25.73 K
|
$1.63 M
|
$1.74 M
|
| Selling, General & Administrative Expenses |
$105.86 M
|
$13.48 M
|
$9.84 M
|
$10.81 M
|
$6.56 M
|
$4.63 M
|
$6.56 M
|
$6.61 M
|
$8.37 M
|
$7.88 M
|
| Other Expenses |
$3.24 M
|
$2.71 M
|
-$712.00 K
|
-$731.00 K
|
$0.00
|
$0.00
|
$6.00 K
|
-$585.95 K
|
-$100.52 K
|
-$183.57 K
|
| Operating Expenses |
$187.67 M
|
$41.38 M
|
$24.40 M
|
$31.53 M
|
$29.76 M
|
$20.90 M
|
$13.73 M
|
$9.68 M
|
$13.55 M
|
$12.19 M
|
| Cost And Expenses |
$187.67 M
|
$41.38 M
|
$24.40 M
|
$31.53 M
|
$31.95 M
|
$23.20 M
|
$13.73 M
|
$9.68 M
|
$15.06 M
|
$12.55 M
|
| Interest Income |
$12.05 M
|
$2.58 M
|
$300.00 K
|
$110.00 K
|
$13.00 K
|
$154.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$231.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$62.00 K
|
$0.00
|
$0.00
|
$3.05 M
|
| Depreciation & Amortization |
$1.99 M
|
$1.96 M
|
$1.96 M
|
$1.96 M
|
$2.19 M
|
$2.30 M
|
$1.92 M
|
$1.61 M
|
$19.70 K
|
$108.23 K
|
| EBITDA |
-$173.63 M |
-$37.03 M |
-$22.10 M |
-$30.30 M |
-$22.45 M |
-$28.48 M |
-$9.92 M |
-$8.07 M |
-$6.72 M |
-$15.80 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.01
|
-4.63
|
-40.77
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.01
|
-9.38
|
-31.38
|
| Total Other Income/Expenses Net |
$11.82 M
|
$2.40 M
|
$330.00 K
|
$618.00 K
|
$7.31 M
|
-$7.58 M
|
$2.46 M
|
-$1.27 M
|
$1.59 M
|
-$3.75 M
|
| Income Before Tax |
-$175.85 M
|
-$38.99 M
|
-$24.07 M
|
-$30.91 M
|
-$24.64 M
|
-$30.77 M
|
-$11.84 M
|
-$13.72 M
|
-$12.04 M
|
-$15.91 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.01
|
-8.3
|
-41.05
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.65 M
|
$21.70 K
|
$0.00
|
| Net Income |
-$175.85 M
|
-$38.99 M
|
-$24.07 M
|
-$30.91 M
|
-$24.64 M
|
-$30.77 M
|
-$13.34 M
|
-$15.67 M
|
-$12.07 M
|
-$15.91 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.01
|
-8.32
|
-41.05
|
| EPS |
-4.38 |
-2.36 |
-2.87 |
-5.81 |
-3.68 |
-15.78 |
-9.54 |
-26.18 |
-58.35 |
-126.58 |
| EPS Diluted |
-4.38 |
-2.36 |
-2.87 |
-5.81 |
-3.68 |
-15.78 |
-9.54 |
-26.18 |
-58.35 |
-126.58 |
| Weighted Average Shares Out |
$40.18 M
|
$16.49 M
|
$8.40 M
|
$5.32 M
|
$4.17 M
|
$2.28 M
|
$1.40 M
|
$598.52 K
|
$206.77 K
|
$125.68 K
|
| Weighted Average Shares Out Diluted |
$40.18 M
|
$16.49 M
|
$8.40 M
|
$5.32 M
|
$4.17 M
|
$2.28 M
|
$1.40 M
|
$598.52 K
|
$206.77 K
|
$125.68 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
